following an abbreviated resubmission:
azelastine hydrochloride plus fluticasone propionate nasal spray (Dymista®) is accepted for use within NHS Scotland.
Indication under review: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
For patients in whom the combination of azelastine hydrochloride and fluticasone propionate nasal spray is an appropriate choice of therapy, Dymista® provides the two ingredients in a single nasal spray.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of Dymista®. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice95KB (PDF)
Medicine details
- Medicine name:
- azelastine hydrochloride + fluticasone propionate (Dymista)
- SMC ID:
- 921/13
- Indication:
- for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
- Pharmaceutical company
- Meda Pharmaceuticals Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 October 2014